Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

@article{Nygaard2014LevelsOC,
  title={Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.},
  author={Anneli Dowler Nygaard and K G Spindler and Niels Pallisgaard and Rikke Fredslund Andersen and Anders Kristian M Jakobsen},
  journal={Oncology reports},
  year={2014},
  volume={31 2},
  pages={969-74}
}
Non-small cell lung cancer (NSCLC) is one of the most common malignant tumours in the western world and is associated with a poor prognosis. Biomarkers predicting prognosis and therapeutic effects are highly required, and cell-free DNA (cfDNA) may be a feasible option. Genetic mutations can be analysed in plasma and may increase the scientific use of such measurements. In the present study, we investigated: i) the dynamics of cfDNA and plasma mutated KRAS (pmKRAS) during the treatment of… CONTINUE READING
10 Citations
24 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version

  • G Engholm, J Ferlay, N Christensen
  • Danish Cancer Society. http://www.ancr.nu…
  • 2013

Quantification of cell free DNA as a prognostic factor in advanced NSCLC

  • AD Nygaard, KL Garm Spindler, N Pallisgaard, RF Andersen, A Jakobsen
  • J Can Ther
  • 2013

The prognostic value of KRAS mutated plasma DNA in advanced non - small cell

  • AD Nygaard, KL GarmSpindler, N Pallisgaard, RF Andersen, A Jakobsen
  • lung cancer
  • 2013

Similar Papers

Loading similar papers…